MedTrace Logo

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

NCT04636775 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2023-12-11

No results posted yet for this study

Summary

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.

Conditions

  • NSCLC Stage IV
  • NSCLC, Recurrent

Interventions

DIAGNOSTIC_TEST

Microbiome

Nasal and buccal swabs, and stool sample, as well as the extracted DNAs

Sponsors & Collaborators

  • Jun Zhang, MD, PhD

    lead OTHER

Principal Investigators

  • Jun Zhang, MD, PhD · The University of Kansas Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-29
Primary Completion
2024-08-30
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04636775 on ClinicalTrials.gov